Corcept Therapeutics Inc (CORT) Stock
NAQ · CORT
110.29
Fundamentals
Market cap
$11.92B
Price / Earnings ratio
229.1x
Price / Sales ratio
14.9x
Price / Book ratio
17.6x
Return on assets
0.1%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Corcept Therapeutics Inc
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
SectorHealthcare
IndustryBiotechnology
Employees730
CEODr. Joseph K. Belanoff M.D.
IPO DateApr 14, 2004
HeadquartersRedwood City, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Joseph K. Belanoff M.D. | Co-Founder, President, CEO & Director | 1957 |
| Mr. Atabak Mokari | CFO & Treasurer | 1977 |
| Mr. Sean Maduck | President of Endocrinology | 1977 |
| Dr. William Guyer Pharm.D. | Chief Development Officer | 1968 |
| Mr. Gary Charles Robb J.D. | Chief Business Officer & Secretary | 1963 |
| Mr. Joseph Douglas Lyon | Chief Technology & Accounting Officer | 1978 |
| Dr. Hazel Hunt Ph.D. | Chief Scientific Officer | 1960 |
| Ms. Amy Flood | Chief Human Resources & Communications Officer | — |
| Ms. Monica Tellado | President of Emerging Markets | 1973 |
| Mr. Roberto W. Vieira | President of Oncology | — |
Fundamentals
Valuation
Market cap$11.92B
Price-to-sales ratio14.94
Price-to-book value17.59
Price-earnings ratio229.10
Return on Equity7.00%
Return on SalesN/A
Return on Assets0.06%
PEG ratio0.81
Earnings Per Share
Earnings Per Share$0.53
Income Statement
Average volume881,545
EBITDA$-6.87M
1 year high (52w)$126.38
1 year low (52w)$28.66
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



